


ROC CURVES: CSF



Supplementary Figure S1. ROC for Vascular Injury and Angiogenesis Biomarkers of aSAH in CSF. The ROC and AUC were calculated for (A) VCAM-1, (B) SAA, (C) ICAM-1, (D) Flt-1, (E) CRP, (F) VEGF, (G) VEGF-C, (H) VEGF-D, and (I) bFGF as they were previously identified to be significantly elevated in the CSF of patients with aSAH when compared to hydrocephalus controls. (A) VCAM-1: N: control: 6, aSAH: 14; (B) SAA: N: control: 8, aSAH: 12 (C) ICAM-1: N: control: 7, aSAH: 14; (D) Flt-1: N: control: 8, aSAH: 12; (E) CRP: N: control: 7, aSAH: 14; (F) VEGF: N: control: 8, aSAH: 13; (G) VEGF-C: N: control: 5 aSAH: 13; (H) VEGF-D: N: control: 7 aSAH: 14; (I) bFGF: N: control: 8 aSAH: 12.

ROC CURVES: Serum




Figure S2. ROC for Vascular Injury and Angiogenesis Biomarkers of aSAH in Serum. The ROC and AUC were calculated for (A) VCAM-1, (B) SAA, (C) CRP, (D) Flt-1, (E) ICAM-1, (F) PIGF, (G) VEGF-C, (H) VEGF-D, and (I) Tie-2 as they were previously identified to be significantly elevated in the serum of patients with aSAH when compared to healthy, age-matched controls. (A) VCAM-1: N: control: 8, aSAH: 15; (B) SAA: N: control: 7, aSAH: 11; (C) CRP: N: control: 8, aSAH: 15; (D) Flt-1: N: control: 8, aSAH: 12; (E) ICAM-1: N: control: 8, aSAH: 15; (F) PIGF: N: control: 8, aSAH: 15; (G) VEGF-C: N: control: 5 aSAH: 13; (H) VEGF-D: N: control: 7 aSAH: 14; (I) Tie-2: N: control: 8, aSAH: 15.

ROC CURVES: Pro-Inflammatory Cytokines in Serum




Figure S3. ROC for Pro-Inflammatory Cytokines of aSAH in Serum. The ROC and AUC were calculated for (A) IL-10, (B) IL-1 β , (C) IL-2, and (D) IL-6. (A) IL-10: N: control: 7, aSAH: 14; (B) IL-1 β : N: control: 9, aSAH: 15; (C) IL-2: N: control: 9, aSAH: 11; (D) IL-6: N: control: 10, aSAH: 15.